Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement awards. On January 2, 2025, the company granted stock options to two new non-executive employees to purchase 72,000 shares at $1.79 per share, which was the closing price on the grant date.
Additionally, one newly-hired non-executive employee received restricted stock units (RSUs) representing 3,200 shares. The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The RSUs will vest in four equal annual installments of 25% each, subject to continuous employment.
Fate Therapeutics (NASDAQ: FATE), una compagnia biofarmaceutica in fase clinica focalizzata su terapie immunologiche derivate da iPSC, ha annunciato nuovi premi per l'induzione dei dipendenti. Il 2 gennaio 2025, l'azienda ha concesso opzioni su azioni a due nuovi dipendenti non esecutivi per l'acquisto di 72.000 azioni a $1,79 per azione, che era il prezzo di chiusura alla data della concessione.
Inoltre, un nuovo dipendente non esecutivo ha ricevuto unità azionarie vincolate (RSU) che rappresentano 3.200 azioni. Le opzioni saranno soggette a maturazione in quattro anni, con il 25% che si matura dopo un anno e il restante 75% che matura mensilmente nei successivi 36 mesi. Le RSU matureranno in quattro rate annuali uguali del 25% ciascuna, soggette a un impiego continuo.
Fate Therapeutics (NASDAQ: FATE), una compañía biofarmacéutica en etapa clínica enfocada en terapias inmunológicas derivadas de iPSC, ha anunciado nuevos premios para la inducción de empleados. El 2 de enero de 2025, la empresa otorgó opciones sobre acciones a dos nuevos empleados no ejecutivos para comprar 72,000 acciones a $1.79 por acción, que era el precio de cierre en la fecha de concesión.
Además, un nuevo empleado no ejecutivo recibió unidades de acciones restringidas (RSUs) que representan 3,200 acciones. Las opciones se consolidarán durante cuatro años, con el 25% acumulándose después de un año y el restante 75% acumulándose mensualmente durante los siguientes 36 meses. Las RSUs se consolidarán en cuatro cuotas anuales iguales del 25% cada una, sujeto a empleo continuo.
Fate Therapeutics (NASDAQ: FATE), 임상 단계의 생물 의약품 회사로 iPSC 유래 세포 면역 요법에 집중하고 있는 이 회사는 새로운 직원 유인 보상을 발표했습니다. 2025년 1월 2일, 이 회사는 72,000주를 주당 $1.79에 구매할 수 있는 주식 옵션을 두 명의 새로운 비상무 직원에게 부여했습니다. 이는 부여일의 종가였습니다.
또한, 한 명의 새로 고용된 비상무 직원은 3,200주를 나타내는 제한 주식 단위(RSU)를 받았습니다. 이 옵션은 4년 동안 분할되어 유효하게 되며, 첫 해가 지나면 25%가 유효하고 남은 75%는 이후 36개월 동안 월별로 유효하게 됩니다. RSU는 4회의 동일한 연간 할당(각각 25%)으로 유효해지며, 지속적인 고용 조건을 충족해야 합니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique axée sur des thérapies immunologiques dérivées de iPSC, a annoncé de nouvelles récompenses pour inciter les employés. Le 2 janvier 2025, l'entreprise a accordé des options d'achat d'actions à deux nouveaux employés non exécutifs pour acheter 72 000 actions à 1,79 $ par action, ce qui correspondait au prix de clôture à la date d'attribution.
De plus, un nouvel employé non exécutif a reçu des unités d'actions restreintes (RSU) représentant 3 200 actions. Les options acquerront des droits sur quatre ans, avec 25 % acquérant des droits après un an et les 75 % restants acquérant des droits chaque mois pendant les 36 mois suivants. Les RSU acquerront des droits en quatre versements annuels égaux de 25 % chacun, sous réserve d'un emploi continu.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf ipSC-abgeleitete zelluläre Immuntherapien konzentriert, hat neue Anreizzahlungen für Mitarbeiter angekündigt. Am 2. Januar 2025 gewährte das Unternehmen zwei neuen nicht-executiven Mitarbeitern Aktienoptionen zum Kauf von 72.000 Aktien zu einem Preis von 1,79 $ pro Aktie, was dem Schlusskurs am Tag der Gewährung entsprach.
Darüber hinaus erhielt ein neu eingestellter nicht-executiver Mitarbeiter beschränkte Aktieneinheiten (RSUs), die 3.200 Aktien repräsentieren. Die Optionen werden über vier Jahre vereinnahmt, wobei 25 % nach einem Jahr und die verbleibenden 75 % monatlich über die nächsten 36 Monate vereinnahmt werden. Die RSUs werden in vier gleichen jährlichen Raten von jeweils 25 % vereinnahmt, vorbehaltlich einer kontinuierlichen Anstellung.
- None.
- None.
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company’s common stock at an exercise price per share of
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
What is the exercise price of FATE's new stock options granted on January 2, 2025?
How many shares were included in FATE's January 2025 employee inducement awards?
What is the vesting schedule for FATE's January 2025 stock option grants?
How do the RSUs vest in FATE's January 2025 inducement awards?
